Stephen Austin - Imprimis Pharmaceuticals Independent Director

Director

Mr. Stephen G. Austin, CPA, is Independent Director of Imprimis Pharmaceuticals, Inc., since July 2012. He has served as our director since July 2012. He was a Partner in Swenson Advisors, LLP, a regional accounting firm, since May 1998 and has served as Managing Partner since October 2006. At Swenson Advisors, Mr. Austin manages assurance, SarbanesOxley and other business consulting for public and private companies with a focus on technology, manufacturing, service, real estate, social media and nonprofit organizations. Prior to joining Swenson Advisors, Mr. Austin accumulated over 22 years of experience as an audit partner with Price Waterhouse LLP, where he worked from 1976 to 1996, and with McGladrey Pullen, LLP, where he worked from 1996 to 1998, serving both public and private companies. He serves as a board member or advisory board member for various notforprofit foundations, associations and public service organizations in the United States, is on the global board of directors of Integra International, an international association of accounting firms, and served as a director on the board of Avanir Pharmaceuticals, Inc. from March 2003 to December 2012, where he also served on the audit committee and compensation committee. In 2004, Mr. Austin published a book on business ethics entitled Rise of the New Ethics Class, and in 2005 and 2006 he published articles in Asia discussing The SarbanesOxley Act of 2002. Mr. Austin has also authored articles for the American Institute of CPAs, including the Journal of Accountancy since 2012.
Age 61
Tenure 12 years
Professional MarksMBA
Phone858-704-4040
Webhttp://www.imprimisrx.com
Austin holds a B.S. degree in accounting from Bob Jones University and an MBA degree from the University of Georgia and was licensed as a Certified Public Accountant since 1978.

Imprimis Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of (11.94) % which means that it has lost $11.94 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (153.09) %, meaning that it created substantial loss on money invested by shareholders. Imprimis Pharmaceuticals' management efficiency ratios could be used to measure how well Imprimis Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
The company currently holds 15.28 M in liabilities with Debt to Equity (D/E) ratio of 343.1, indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. Imprimis Pharmaceuticals has a current ratio of 1.11, suggesting that it may not be capable to disburse its financial obligations when due. Debt can assist Imprimis Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Imprimis Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Imprimis Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Imprimis to invest in growth at high rates of return. When we think about Imprimis Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Showing other executives

DIRECTOR Age

Jeanine LiokoBarrick Gold Corp
52
Michael EvansBarrick Gold Corp
60
Brett HarveyBarrick Gold Corp
67
Ernie ThrasherBarrick Gold Corp
61
Neil SimpkinsSummit Materials
51
Safiatou BaNDawBarrick Gold Corp
64
Andrew QuinnBarrick Gold Corp
66
Brian GreenspunBarrick Gold Corp
73
Steven ShapiroBarrick Gold Corp
65
Anne WadeSummit Materials
48
Kadri DagdelenBarrick Gold Corp
60
Karl VoltaireBarrick Gold Corp
63
Pablo MarcetBarrick Gold Corp
53
Robert PrichardBarrick Gold Corp
68
Steven WunningSummit Materials
70
Anne CooneySummit Materials
61
Jemaluddin KassumBarrick Gold Corp
68
John MurphySummit Materials
70
Graham ClowBarrick Gold Corp
66
Anthony MunkBarrick Gold Corp
57
Olivia KirtleyBarrick Gold Corp
66
Imprimis Pharmaceuticals, Inc., an ophthalmology-focused pharmaceutical company, engages in the development, production, and sale of medications to physicians and patients in the United States. Imprimis Pharmaceuticals, Inc. was founded in 1998 and is headquartered in San Diego, California. Imprimis Pharmaceuticals operates under Drug Manufacturers - Specialty Generic classification in USA and is traded on BATS Exchange. It employs 128 people. Imprimis Pharmaceuticals (IMMY) is traded on NASDAQ Exchange in USA and employs 128 people.

Management Performance

Imprimis Pharmaceuticals Leadership Team

Elected by the shareholders, the Imprimis Pharmaceuticals' board of directors comprises two types of representatives: Imprimis Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Imprimis. The board's role is to monitor Imprimis Pharmaceuticals' management team and ensure that shareholders' interests are well served. Imprimis Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Imprimis Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
William Nelson, Director
Robert Kammer, Chairman of the Board
Clayton Edwards, COO
John Saharek, Chief Commercial Officer
Anthony Principi, Independent Director
Andrew Boll, Vice President - Accounting and Financial Reporting
Mark Baum, CEO, Director
Richard Lindstrom, Director
Stephen Austin, Independent Director

Imprimis Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Imprimis Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
Check out Risk vs Return Analysis to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Other Consideration for investing in Imprimis Stock

If you are still planning to invest in Imprimis Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Imprimis Pharmaceuticals' history and understand the potential risks before investing.
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Portfolio Analyzer
Portfolio analysis module that provides access to portfolio diagnostics and optimization engine
Commodity Directory
Find actively traded commodities issued by global exchanges
AI Portfolio Architect
Use AI to generate optimal portfolios and find profitable investment opportunities
Portfolio Rebalancing
Analyze risk-adjusted returns against different time horizons to find asset-allocation targets
Stock Screener
Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook.
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Economic Indicators
Top statistical indicators that provide insights into how an economy is performing
Correlation Analysis
Reduce portfolio risk simply by holding instruments which are not perfectly correlated
Equity Search
Search for actively traded equities including funds and ETFs from over 30 global markets
Odds Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets